Skip to main content
SpringerLink
Log in

Contraception hormonale masculine par les androgènes seuls. Acquis et perspectives

  • Chapter
La contraception masculine

Part of the book series: L’homme dans tous ses états ((L’homme dans tous ses états))

  • 496 Accesses

Résumé

Affirmer qu’hommes et femmes devraient avoir la liberté de choisir un mode de contraception qui leur convienne paraît aller de soi. Cette liberté implique l’accès à des méthodes analogues pour les deux sexes. Ce choix existe bien pour les contraceptions mécaniques (contraception vaginale/préservatif ; stérilisations). Mais alors que 100 millions de femmes utilisent une contraception hormonale, il n’existe pas (théoriquement) de traitement comparable pour les hommes. Le développement d’une contraception hormonale masculine (CHM) est pourtant souhaité, aussi bien par les femmes que par les hommes. Plusieurs enquêtes ont bien caractérisé cette demande. En France, en 1991, 54 % des hommes se disaient prêts à utiliser une contraception hormonale (Louis Harris) ; en 2000, ils étaient 66 % à exprimer cette opinion (Institut CSA). Ce choix était justifié par un souhait d’alternance dans le couple ou par les échecs et les effets indésirables de la contraception féminine.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Soufir JC, Jouannet P, Soumah A (1983) Male contraception effect on sperm production andgonadotrophin secretion of percutaneous testosterone alone or combined with oral medroxyprogesterone acetate. Society for the Study of Fertility, Manchester

    Google Scholar 

  2. McLachlan RI, McDonald J, Rushford D et al. (2000) Efficacy and acceptability of testosterone implants, alone or in combination with a 5-alpha-reductase inhibitor, for male hormonal contraception. Contraception 62: 73–8

    Article  PubMed  CAS  Google Scholar 

  3. Guérin JF, Rollet J (1988) Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens. Int J Androl 11:187–99

    Article  PubMed  Google Scholar 

  4. Behre HM, Baus S, Kliesch S et al. (1995) Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders. J Clin Endocrinol Metab 80: 2394–403

    Article  PubMed  CAS  Google Scholar 

  5. Knuth UA, Behre H, Belkien L el al. (1985) Clinical trial of 19-nortestosteronehexoxyphenylpropionate (Anadur) formale fertility regulation. Fertil Steril 44: 814–21

    PubMed  CAS  Google Scholar 

  6. Heller CG, Nelson WO, Hill IB (1950) Improvement in spermatogenesis following depression ol human testis with testosterone. Fertil Steril 1: 415–22

    PubMed  CAS  Google Scholar 

  7. Heckel NJ, McDonald JH (1952) The effects of testosterone propionate upon spermatogenetic function of the human testis. Ann NY Acad Sci 55: 725–33

    Article  PubMed  CAS  Google Scholar 

  8. Steinberger E (1977) Effect of chronic administration of testosterone enanthate on sperm production and plasma testosterone, follicle stimulating hormone levels: preliminary evaluation of a possible male contraceptive. Fertil Steril 12: 1320–8

    Google Scholar 

  9. Capell PT, Paulsen CA (1972) The effect of exogenous testosterone upon serum FSH and LH concentrations in normal males. Contraception 6: 135–43

    Article  PubMed  CAS  Google Scholar 

  10. Paulsen CA, Noonan E, Rost E, Meriggiola MC (1992) Studies on the induction of azoospermia/oligozoospermia using testosterone as a contraceptive agent in normal men. ASRM Annual meeting, Poster 0–112

    Google Scholar 

  11. Swerdloff RS, Palacios A, McClure RS et al. (1978) Male contraception: clinical assesment of chronic administration of testosterone enanthante. Int J Androl suppl. 2: 731

    Article  CAS  Google Scholar 

  12. Swerdloff RS, Campfield LA, Palacios A, McClure RD (1979) Suppression of human spermalogenesis by depot androgen: potential lor male contraception. J Steroid Biochem 11: 663–70

    Article  PubMed  CAS  Google Scholar 

  13. WHO. Task Force on methods for the regulation of male fertility (1990) Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 336: 955–9

    Google Scholar 

  14. WHO. Task Force on methods for the regulation of male fertility (1996) Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril 65: 821–9

    Google Scholar 

  15. Barfield A, Melo J, Coutinho F et al. (1979) Pregnancies associated with sperm concentration below 10 millions/mL in clinical studies of potential male contraceptive method monthly depot acetate medroxyprogesterone acetate and testosterone esters. Contraception 20: 121–7

    Article  PubMed  CAS  Google Scholar 

  16. Wu FC (1996) Male Contraception. Bailleres Clin Obst Gynaecol: 1–23

    Google Scholar 

  17. Handelsman DJ, Farley TM, Peregoudov A, Waites GM, World Health Organization Task Force on Methods for the Regulation of Male Fertility (1995) Factors in nonuniform induction of azoospermia by testosterone enanthate in normal men. Fertil Steril 63:125–33

    Google Scholar 

  18. Eckardstein SV, Schmidt A, Kamischke A et al. (2002) GAG repeat length in the androgen receptor gene and gonadotrophin suppression influence the effectiveness of hormonal male contraception. Clin Endocrinol (Oxf) 57: 647–55

    Article  CAS  Google Scholar 

  19. Anderson RA, Wallace AM, Wu FC (1996) Comparison between testosterone enanthate induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone. J Clin Endocrinol Metab 81: 902–8

    Article  PubMed  CAS  Google Scholar 

  20. Hikim AP, Wang C, Lue Y et al. (1998) Spontaneous germ cell apoptosis in humans: evidence for ethnic differences in the susceptibility of germ cells to programmed cell death. J Clin Endocrinol Metab 83:152–6

    Article  PubMed  CAS  Google Scholar 

  21. Zhang GY, Gu YQ, Wang XH et al. (1999) A clinical trial of injectable testosterone undecanoate as a potential male contraceptive in normal Chinese men. J Clin Endocrinol Metab 84: 3642–7

    Article  PubMed  CAS  Google Scholar 

  22. Gu YQ, Wang XH, Xu D et al. (2003) A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J Clin Endocrinol Metab 88: 562–8

    Article  PubMed  CAS  Google Scholar 

  23. Gu Y, Liang X, Wu W et al. (2009) Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men. J Clin Endocrinol Metab 94: 1910–5

    Article  PubMed  CAS  Google Scholar 

  24. Nieschlag E, Vorona E, Wenk M et al. (2011) Hormonal male contraception in men with normal and subnormal semen parameters. Int J Androl 34: 556–67

    Article  PubMed  CAS  Google Scholar 

  25. Martin CW, Anderson RA, Cheng L el al. (2000) Potential impact of hormonal male contraception: cross-cultural implications for development of novel preparations. Hum Reprod 15: 637–45

    Article  PubMed  CAS  Google Scholar 

  26. Turner L, Conway AJ, Jimenez M et al. (2003) Contraceptive efficacy of a depot progestin and androgen combination in men. J Clin Endocrinol Met ab 88: 4659–67

    Article  CAS  Google Scholar 

  27. Page ST, Amory JK, Anawalt BD et al (2006) Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition ol a GnRH antagonist. J Clin Endocrinol Metab 91:4374–80

    Article  PubMed  CAS  Google Scholar 

  28. Soufir JC, Meduri G, Ziyyat A (2011) Spermatogenetic inhibition in men taking a combination of oral medroxyprogesterone acetate and percutaneous testosterone as a male contraceptive method. Hum Reprod 26: 1708–14

    Article  PubMed  CAS  Google Scholar 

  29. Aaltonen P, Amory JK, Anderson RA et al. (2007) 10th Summit Meeting consensus: recommendations for regulatory approval for hormonal male contraception, http://www.ncbi.nlm.nih.gov/pubmed/ J Androl 28: 362–3

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Biologie de la reproduction, groupe hospitalier Cochin 123, bd de Port Royal, 75014, Paris, France

    J.-C. Soufir

Authors
  1. J.-C. Soufir
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J.-C. Soufir .

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag France

About this chapter

Cite this chapter

Soufir, JC. (2013). Contraception hormonale masculine par les androgènes seuls. Acquis et perspectives. In: La contraception masculine. L’homme dans tous ses états. Springer, Paris. https://doi.org/10.1007/978-2-8178-0346-3_4

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0346-3_4

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0345-6

  • Online ISBN: 978-2-8178-0346-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation